Guideline‑Recommended Direct‑Acting Antiviral Regimens for Chronic Hepatitis C

General Treatment Recommendation

• The American Association for the Study of Liver Diseases (AASLD) recommends that all adults with chronic hepatitis C infection receive a pangenotypic direct‑acting antiviral (DAA) regimen—either sofosbuvir/velpatasvir for 12 weeks or glecaprevir/pibrentasvir for 8 weeks in treatment‑naïve patients without cirrhosis—because cure rates (SVR12) exceed 95 % in these populations. [1][2]

First‑Line Regimens by Clinical Scenario

1. Treatment‑Naïve Patients Without Cirrhosis (All Genotypes 1‑6)

• Sofosbuvir/velpatasvir 400 mg/100 mg once daily for 12 weeks achieves SVR12 rates > 95 % in this group. (Strong recommendation) [1][2]3
• Glecaprevir/pibrentasvir once daily for 8 weeks also achieves SVR12 rates > 95 %. (Strong recommendation) [1][2]3
• Routine HCV genotyping is not required before initiating these pangenotypic regimens in treatment‑naïve patients without cirrhosis. (Strong recommendation) 4

2. Treatment‑Naïve Patients With Compensated Cirrhosis (Child‑Pugh A)

• Genotype 3 with compensated cirrhosis requires intensified therapy because dual‑DAA regimens alone have higher failure rates. (Strong recommendation) [2][5]
• If baseline testing shows the NS5A Y93H resistance‑associated substitution, ribavirin addition or triple‑DAA therapy is mandatory. (Strong recommendation) [2][5]3

3. Treatment‑Experienced Patients

• Genotyping is required for all treatment‑experienced patients because regimen choice and duration differ by genotype. (Strong recommendation) 4

4. Decompensated Cirrhosis (Child‑Pugh B or C)

• Protease‑inhibitor‑containing regimens (e.g., glecaprevir/pibrentasvir) are absolutely contraindicated due to markedly increased drug exposure and toxicity. (Strong recommendation) [5][6]
• Sofosbuvir/velpatasvir for 12 weeks is the preferred pangenotypic regimen. (Strong recommendation) [5][6]
• Add weight‑based ribavirin when tolerated to further improve SVR rates. (Conditional recommendation) 5
• If ribavirin cannot be used, extend sofosbuvir/velpatasvir to 24 weeks (without ribavirin). (Conditional recommendation) [5][7]
• Treatment with sofosbuvir/velpatasvir improves liver function tests, MELD scores, and overall hepatic reserve in decompensated patients. (Strong recommendation) 5

Essential Pre‑Treatment Evaluation

• Quantitative HCV RNA testing to confirm active viremia and establish baseline viral load. (Strong recommendation) 4
• Liver fibrosis staging using non‑invasive scores (FIB‑4, APRI) or transient elastography; biopsy if needed. (Strong recommendation) 4
• Screen for hepatitis B and HIV coinfection because they accelerate fibrosis progression. (Strong recommendation) 4
• Vaccinate against hepatitis A and B in susceptible individuals. (Strong recommendation) 4
• Administer pneumococcal vaccine to all patients with cirrhosis. (Strong recommendation) 4

When Genotyping Is Required

• All treatment‑experienced patients (prior DAA or interferon failure). (Strong recommendation) 4
• Patients originating from sub‑Saharan Africa, China, or Southeast Asia to detect rare subtypes and NS5A resistance. (Strong recommendation) [1][3]
• Rare subtypes (e.g., 1l, 4r, 3b, 3g, 6u, 6v) that harbor NS5A resistance‑associated substitutions should receive sofosbuvir/velpatasvir/voxilaprevir. (Strong recommendation) [1][2]3

When Genotyping Is NOT Required

• Treatment‑naïve patients without cirrhosis using pangenotypic regimens. (Strong recommendation) 4

Patient Counseling & Management

• Alcohol abstinence is advised for all patients; no safe level of alcohol exists with chronic HCV. (Strong recommendation) 4
• Patients with alcohol‑use disorder should be referred to an addiction specialist. (Strong recommendation) 4
• Ongoing alcohol use does not contraindicate DAA therapy; adherent patients achieve cure rates comparable to abstinent patients. (Strong recommendation) 4

Special Populations

Post‑Liver Transplant Recipients

• Initiate DAA therapy ≈ 3 months after transplant once the patient is clinically stable. (Strong recommendation) 7
• Sofosbuvir/velpatasvir for 12 weeks—no adjustment of immunosuppressant dosing required. (Strong recommendation) 7
• Glecaprevir/pibrentasvir for 12 weeks—requires close monitoring and possible dose adjustment of immunosuppressants. (Conditional recommendation) 7
• For decompensated post‑transplant cirrhosis, use sofosbuvir/velpatasvir + ribavirin for 12 weeks. (Strong recommendation) 7

Kidney Transplant Recipients

• Direct‑acting antivirals achieve ≈ 97 % cure in kidney‑transplant patients. (Strong recommendation) 7
• In the MAGELLAN‑2 study, glecaprevir/pibrentasvir for 12 weeks yielded 100 % SVR12. (Strong recommendation) 7

Common Pitfalls to Avoid

• Do not delay treatment for patients with active substance use; injection drug use is not a contraindication if adherence can be ensured. (Strong recommendation) 4
• Avoid protease‑inhibitor‑containing regimens (e.g., glecaprevir/pibrentasvir) in decompensated cirrhosis. (Strong recommendation) [5][6]
• Do not undertreat genotype 3 with cirrhosis; intensified therapy with ribavirin or triple‑DAA regimens is required. (Strong recommendation) [2][5]
• Do not assume genotyping is always necessary; pangenotypic regimens eliminate this requirement for most treatment‑naïve patients without cirrhosis. (Strong recommendation) 4

Emerging Evidence

• A 2025 randomized controlled trial showed sofosbuvir‑daclatasvir to be non‑inferior to sofosbuvir‑velpatasvir (97 % vs 95 % SVR12), suggesting a potential cost‑effective alternative where available. (Evidence level: moderate) — however, AASLD continues to recommend sofosbuvir/velpatasvir and glecaprevir/pibrentasvir as first‑line options. (Strong recommendation) [1][2]

Retreatment of Hepatitis C After Sofosbuvir/Velpatasvir Failure: Evidence‑Based Recommendations

Pre‑Retreatment Evaluation

• Perform HCV genotyping and subtyping to identify rare subtypes (1l, 4r, 3b, 3g, 6u, 6v) that may carry baseline NS5A resistance. 8
• Obtain NS5A resistance‑associated substitution (RAS) testing (population or deep sequencing, ≥15 % cutoff) in patients originating from sub‑Saharan Africa, China, or Southeast Asia, where rare subtypes and NS5A resistance are prevalent. 8

Safety Considerations

• Protease‑inhibitor‑containing regimens (including sofosbuvir/velpatasvir/voxilaprevir) are absolutely contraindicated in patients with decompensated cirrhosis (Child‑Pugh B or C) because of markedly increased drug exposure and hepatotoxicity risk. 9
• If decompensated cirrhosis has developed, retreatment should use sofosbuvir/velpatasvir + ribavirin for 12 weeks rather than the triple‑DAA regimen. 9

Genotype‑Specific Retreatment Nuances

• Genotype 3 infection with compensated cirrhosis represents the most challenging retreatment scenario due to intrinsically higher resistance rates. 8
• First‑line retreatment for genotype 3 with compensated cirrhosis remains sofosbuvir/velpatasvir/voxilaprevir for 12 weeks; if unavailable, alternatives are sofosbuvir/velpatasvir + ribavirin for 12 weeks or glecaprevir/pibrentasvir for 16 weeks. 8
• Presence of the NS5A Y93H substitution mandates intensified therapy, either by adding ribavirin or by using the triple‑DAA regimen (sofosbuvir/velpatasvir/voxilaprevir). 8
• Patients infected with rare subtypes (1l, 4r, 3b, 3g, 6u, 6v) that harbor ≥1 NS5A RAS should receive sofosbuvir/velpatasvir/voxilaprevir as first‑line retreatment. 8

Contraindicated or Discouraged Regimens

• Glecaprevir/pibrentasvir should not be used for retreatment after sofosbuvir/velpatasvir failure unless sofosbuvir/velpatasvir/voxilaprevir is unavailable, because it lacks a protease inhibitor component (voxilaprevir) essential for overcoming prior NS5A inhibitor exposure. 8
• Sofosbuvir/velpatasvir/voxilaprevir must not be used in decompensated cirrhosis, as the protease‑inhibitor component is contraindicated and can precipitate hepatic decompensation. 9

Pre‑treatment Evaluation and First‑line Therapy for Chronic Hepatitis C (cited)

Pre‑treatment Assessment

• Confirm active HCV replication with a quantitative HCV‑RNA (or core antigen) test before initiating therapy. 10
• Stage liver fibrosis using non‑invasive scores (e.g., FIB‑4, APRI) or transient elastography to identify the presence or absence of cirrhosis. 10
• Perform a thorough review of concomitant medications and adjust doses as needed to avoid clinically significant drug‑drug interactions. 10

Genotype Testing Recommendations

• In treatment‑naïve adults without cirrhosis, genotype determination is not required; pangenotypic direct‑acting antiviral (DAA) regimens can be started immediately. This simplification improves treatment access and raises overall cure rates. 10
• For patients with compensated cirrhosis and genotype 3, genotype testing is required to select the optimal regimen and treatment duration. 10

First‑line Pangenotypic Regimens

• Glecaprevir/pibrentasvir for 8 weeks achieves sustained virologic response at week 12 (SVR12) in >95 % of treatment‑naïve, non‑cirrhotic patients. 10
• Sofosbuvir/velpatasvir for 12 weeks also yields SVR12 rates >95 % in the same population. 10

Treatment Duration When Fibrosis Staging Is Unavailable

• Apply a universal 12‑week treatment course for any DAA regimen when fibrosis stage cannot be determined, regardless of genotype. Slightly lower SVR12 rates may be seen in genotype 3 patients with compensated cirrhosis, but effective retreatment strategies are available. 10

Post‑treatment Monitoring

• Routine SVR testing can be omitted in adherent patients because of the high expected cure rates, except in individuals with high‑risk behaviors or reinfection risk; these patients should have SVR testing at 12 weeks post‑therapy and annually thereafter when feasible. 10

Management of Compensated Cirrhosis Due to Hepatitis C

First‑Line Regimens for Most Genotypes

• For patients with compensated (Child‑Pugh A) cirrhosis, the preferred options are either sofosbuvir + velpatasvir for 12 weeks or glecaprevir + pibrentasvir for 8 weeks; these regimens are pangenotypic and applicable to genotypes 1, 2, 4, 5, 6. [11][12]
• Both regimens are classified as A1‑level evidence in the European Association for the Study of the Liver (EASL) guidelines, indicating a strong recommendation based on high‑quality data. [11][12]

Genotype 3‑Specific Therapy (Intensified Regimens Required)

• Genotype 3 infection in compensated cirrhosis requires intensified therapy because dual‑DAA regimens alone have higher failure rates. [11][13]
• Resistance‑guided approach:
  
  • If baseline NS5A resistance testing detects the Y93H substitution, treatment must include either sofosbuvir + velpatasvir + ribavirin or the triple‑DAA sofosbuvir + velpatasvir + voxilaprevir.
  • In the absence of Y93H, sofosbuvir + velpatasvir alone for 12 weeks is acceptable. [11][14]

Pre‑Treatment Assessment

• Confirm compensated status by determining the Child‑Pugh classification (must be Class A) before initiating therapy. [11][12]

Safety Contra‑Indications (Protease‑Inhibitor Regimens)

• Protease‑inhibitor‑containing regimens (glecaprevir + pibrentasvir or sofosbuvir + velpatasvir + voxilaprevir) must not be used in any patient with a history of hepatic decompensation, even if they are currently Child‑Pugh A. [12][15]16
• These regimens are associated with substantially higher drug exposure and increased risk of hepatotoxicity in patients with prior decompensation. [12][15]16

Pitfalls to Avoid in Genotype 3 Management

• Do not treat genotype 3 compensated cirrhosis with sofosbuvir + velpatasvir alone without ribavirin or a third agent; genotype 3 has intrinsically higher resistance rates and requires intensified therapy to achieve optimal cure rates. [11][13]

Hepatitis C Treatment Recommendations for Patients with Cirrhosis

Assessment and Eligibility

• Calculate the Child‑Pugh score; a score of 5–6 confirms compensated (Class A) cirrhosis, whereas any score ≥ 7 or a prior decompensation episode excludes patients from simplified treatment algorithms. 17
• Perform abdominal ultrasound within the preceding 6 months to screen for hepatocellular carcinoma and subclinical ascites; detection of either finding mandates referral to a hepatology specialist. 17
• Obtain a complete blood count, INR, hepatic function panel, and estimated glomerular filtration rate within 3 months before initiating antiviral therapy. 17
• Test for hepatitis B surface antigen and HIV infection before starting direct‑acting antivirals, because coinfection accelerates fibrosis progression. 17

First‑Line Regimens for Compensated Cirrhosis (Child‑Pugh A)

• Genotype testing is not required before starting these pangenotypic regimens for treatment‑naïve compensated patients (except genotype 3). 17

Genotype 3‑Specific Recommendations (Compensated Cirrhosis)

• In the ASTRAL‑4 trial, genotype 3 patients with decompensated cirrhosis achieved 50 % SVR with Sofosbuvir/Velpatasvir alone versus 85 % SVR when ribavirin was added. 18

Safety Warning for Protease‑Inhibitor‑Containing Regimens

• Protease‑inhibitor‑containing combinations (Glecaprevir/Pibrentasvir, Sofosbuvir/Velpatasvir/Voxilaprevir) are contraindicated in any patient with a history of hepatic decompensation, even if currently classified as Child‑Pugh A, because of markedly increased drug exposure and hepatotoxicity risk. 18

Management of Decompensated Cirrhosis (Child‑Pugh B/C)

• Sofosbuvir + Velpatasvir is the only safe pangenotypic regimen for decompensated cirrhosis; ribavirin is added for most patients to optimize SVR. Protease‑inhibitor regimens are absolutely contraindicated. [17][18]

• Adding weight‑based ribavirin markedly improves SVR, especially for genotype 3 (50 % without ribavirin vs 85 % with ribavirin in ASTRAL‑4). 18
• If ribavirin cannot be tolerated, extending Sofosbuvir/Velpatasvir to 24 weeks without ribavirin restores high SVR rates. 18

Clinical Benefits of Achieving SVR in Decompensated Cirrhosis

• SVR with Sofosbuvir/Velpatasvir improves bilirubin, albumin, INR, and MELD scores. 18
• Among patients with baseline MELD < 15, 51 % improved, 22 % remained stable, and 27 % worsened at 12 weeks post‑treatment; among those with MELD > 15, 81 % showed improvement. 18

• Approximately 31 % of patients were delisted from liver‑transplant waiting lists after SVR, a benefit confined to those with MELD < 20. 18

• Decompensated patients should be managed in experienced centers with ready access to liver transplantation, and therapy must be stopped if worsening decompensation occurs. 18

Post‑Treatment Monitoring

• Perform HCV RNA testing and hepatic aminotransferase measurement ≥ 12 weeks after completing DAA therapy to confirm sustained virologic response (SVR). 17
• An undetectable HCV RNA at this time point defines virologic cure. 17
• Lifelong hepatocellular carcinoma surveillance with ultrasound every 6 months remains mandatory for all cirrhotic patients, even after SVR. 17
• If treatment fails or is delayed, reassess liver disease status every 6–12 months. 17
• Counsel all patients to avoid excess alcohol consumption to prevent further hepatic injury. 17

Common Pitfalls to Avoid

• Do not use protease‑inhibitor‑containing regimens in decompensated cirrhosis or in any patient with a prior decompensation episode—this is an absolute contraindication. [17][18]
• Do not undertreat genotype 3 infection in compensated cirrhosis; dual‑DAA therapy alone leads to high failure rates and requires ribavirin addition or a triple‑DAA regimen. 18
• Do not assume genotyping is always required; pangenotypic regimens eliminate the need for genotype testing in treatment‑naïve compensated patients (except genotype 3). 17